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Introduction
Triple-negative breast carcinomas (TNBC), which are negative for estrogen/progesterone (ER/PR) receptor expression and lack HER2 overexpression, account for 15% to 20% of breast cancers. TNBC differ from other subtypes of breast cancer in terms of axillary lymph node involvement, locoregional recurrence, time to metastasis (these patients have a high risk of early relapse and much lower survival in the first three to five years after treatment) and patterns of distant recurrence (1) . TNBC is emerging as a highly heterogeneous disease in terms of histological features, clinical behavior and sensitivity to systemic treatments (1 ; DOI: 10.1158/1078-0432.CCR- major improvements in the treatment of this subgroup of tumors, apart from chemotherapy (anthracycline-and taxane-based chemotherapy regimens), which has reduced mortality by about 30% (2) .
Cytotoxic chemotherapy is currently the only treatment option for TNBC. For TNBC patients, a pathological complete response (pCR) to NAC is associated with prolonged overall and event-free survival times (3) (4) (5) . Although the rate of pCR following standard NAC is significantly higher for TNBC as compared to the other breast cancer subtypes, more than 50% of TNBC patients treated in the neoadjuvant setting have residual disease and are associated to an increased risk of distant recurrence, particularly during the first three years after treatment, and a poor outcome. This paradox may be explained by the presence of residual disease in more than half the patients (>60%).
At present, there is no standard of care for adjuvant treatment in TNBC patients with residual disease after NAC, and chemotherapy in patients with metastatic disease is of limited efficacy.
Preclinical studies focusing on residual tumors after NAC could provide an important tool to identify efficient therapies and predictive biomarkers in tumors showing resistance to NAC (6) . In this study, we established patient-derived xenografts (PDX) from residual breast tumors after NAC and found that capecitabine was an effective chemotherapy agent in 60% of TNBC models. We also identified the expression of thymidylate phosphorylase (TYMP) and RB as biomarkers predictive of the response to capecitabine.
Materials and Methods

Patient-derived xenografts
Female Swiss nude mice were purchased from Charles River (Les Arbresles, France) and maintained under specific pathogen-free conditions. Their care and housing were in accordance with institutional guidelines and the rules of the French Ethics Committee (project authorization no. 02163.02).
Patient-derived xenografts were established from primary breast cancer patients with residual
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Author Manuscript Published OnlineFirst on ; DOI: 10.1158/1078-0432.CCR- disease after neoadjuvant chemotherapy, with informed consent from the patient, in accordance with published protocols (7, 8) . For two patients (#90 and #95) xenografts were established from a local breast cancer recurrence treated by NAC. These two patients were excluded frm the diseasefree survival analysis.
Histology and immunohistochemistry status (ER, PR and HER2) was determined for the PDX and compared with that of the patient tumors, as described elsewhere (7, 9) . The PDX derived from primary tumors have been described elsewhere (7, 8, 10) .
Adriamycin (DOX, doxorubicin, Teva Pharmaceuticals, Paris, France), docetaxel (Sanofi Aventis, Marly-la-Ville, France), cisplatin (CDDP, Teva) and cyclophosphamide (Endoxan, Baxter, Maurepas, France) were administered by the intraperitoneal (ip) route, at doses of 2 mg/kg, 20 mg/kg, 6 mg/kg and 100 mg/kg, respectively, every three weeks. Capecitabine (Xeloda, Roche Laboratories, Nutley, NJ) was administered per os at a dose of 540 mg/kg/day, q5d x 6 weeks. Paclitaxel (Fresenius Kabi France) was administered weekly, at a dose of 20 mg/kg (ip), and bevacizumab (Roche, BoulogneBillancourt, France) was administered at a dose of 10 mg/kg (ip) every three weeks. Trastuzumab (Roche) was administered weekly, at a dose of 10 mg/kg. Fluorouracil (5-FU) (Fresenius Kabi France) was administered at a dose of 50 mg/kg (ip) and navelbine (Pierre Fabre Laboratories, France) was administered at a dose of 3 mg/kg (iv) every two weeks. The doses for drug combinations were determined in tolerance studies, based on human equivalences (11) and clinical schedules.
Relative tumor volumes (RTVs) and the percent tumor growth inhibition (TGI) were calculated as previously described (7) . Kaplan-Meier survival analysis was performed on HBCx-95 xenografts treated with various chemotherapy regimens, with GraphPad Prism software (San Diego, CA). An event was defined as a quadrupling of tumor volume from the initial tumor volume (12) .
Percent change in tumor volume was calculated for each tumor as (Vf-V0/V0)*100 where V0 = initial volume (at the beginning of treatment) and Vf= final volume (at the end of treatment). Tumor regression (R) was defined as a decrease in tumor volume of at least 50% taking as reference the baseline tumor volume; at least a 35% increase in tumor volume identified progressive disease (PD) and responses that were between +35% and -50% were considered as stable disease (SD) (13) .
Categorical variables were analyzed with Fisher's exact test. The statistical significance of TGI was determined in Mann-Whitney U tests.
Statistical analysis of the patients' clinical data
We analyzed the clinical parameters of 12 patients in the residual disease group (two patients receiving neoadjuvant chemotherapy for local breast cancer relapse were excluded) and 30 patients in the primary tumor group.
The clinical data for the patients are expressed as frequencies for qualitative variables or medians and associated range for quantitative variables. They were compared in Chi-squared or Fisher's exact tests, as appropriate. Disease-free probabilities were estimated by the Kaplan-Meier method, and survival curves were compared in log-rank tests. Analyses were performed with survival and ggplot2 R libraries.
Targeted next-generation sequencing
DNA extraction and targeted next-generation sequencing of TP53, BRCA1 and BRCA2 were performed by the ICGex NGS platform of Institut Curie, as previously described (14) . Germline BRCA1 and BRCA2 mutations (BRCA1: p.E849X; BRCA2: p.T1282fs ) were present in both the initial tumors and the PDX.
RNA extraction and RT-PCR analysis
RNA extraction and RT-qPCR were performed as previously described (10, 15) . For gene normalization, we used the human TATA box-binding protein (TBP, GeBbank accession no. NM_003194). We used protocols for cDNA synthesis and PCR amplification described in detail elsewhere (16, 17) . The results are expressed as N-fold differences in target gene expression relative to the TBP gene. In the pharmacodynamics analysis, these N-fold differences values for each xenograft were subsequently normalized to yield a median value of 1 for the control xenograft group.
Microarray data analysis
GeneChip Human 1.1 ST arrays were hybridized according to Affymetrix recommendations, using the Ambion WT Expression Kit protocol (Life Technologies) and Affymetrix labeling and hybridization kits.
All analyses were performed with R software (version 3.3; R Core Team 2017) and Bioconductor packages (version 3.4) (18) . Arrays were normalized according to the RMA normalization procedure from oligo package (19) . Differential expression between PDX responding and resistant to capecitabine was assessed by a linear model method, with the Limma package (20) . We used the false discovery rate (FDR) procedure to adjust for multiple testing. We considered log fold changes in expression > 1.5, and p-values < 0.05 to be statistically significant.
RB1 silencing and cell proliferation assays
The HBCc-12A cell line was established from the residual TNBC PDX HBCx-12A by mechanical dissociation and removal of cellular debris and erythrocytes. The HBCc-12A cell line and the HBCx-12A PDX were genotyped with the GenePrint® 10 System (#B9510, Promega) that allows coamplification and three-color detection of nine human loci. The cell line was grown at 37°C in DMEM Glutamax medium supplemented with 10% Fetal Bovine Serum, 1% Penicillin Streptomycine, 1% Hepes Buffer, 1% Sodium Pyruvate and 10 µg/ml Insulin (Sigma) . 
Western blot
For western blot analyses, 115x 10 3 HBCc-12A cells were plated into 6-well culture plates. siRNA and 5-FU were added at the same concentrations and timelines of MTT proliferation assays. Proteins were extracted as described previously (8) . Lysates were resolved on 4-12% TGX gels (Bio-Rad®), 
Results
Residual tumors are characterized by high take rates and poor survival of the corresponding patients
We established 22 PDX by transplanting 53 breast tumors from patients with residual disease after NAC. The take rates for the ER+, HER2+ and triple-negative subtypes were 23%, 22% and 78%, respectively (Supplementary Table 1) . When compared to PDX derived from treatment-naïve primary tumors, previously reported (7, 9) , take rates of residual tumors were higher for ER+ and triplenegative subtypes (Fig. 1A and Supplementary Table S1 ). In the TNBC group, median PDX latency after engraftment was 67 days for residual tumors, versus 160 days for treatment-naïve primary tumors (Fig. 1B) . With a high tumor take and a short latency, residual TNBC PDX may provide an opportunity for preclinical testing of anticancer agents prior to relapse in patients. We therefore retrospectively compared the metastasis-free survival (MFS) of the patients with the latency periods of the 14 PDX established from the residual tumours (Fig. 1C) . Ten of these patients presented a recurrence of metastatic disease, three remain metastasis-free and one died five months after mastectomy (HBC-12A, an 89-year-old patient). PDX latencies were considerably shorter than MFS for eight patients (p=0.021, paired t-test).
The clinical characteristics of patients in the residual disease and primary tumors groups are summarized in Supplementary Table 2 residual disease group of patients, for whom survival was 28% at 25 months, versus 75% for the patients in the primary tumor group (p=0.048, log-rank test) (Fig. 1D ).
These results highlight the aggressive phenotype of residual tumors, with high tumor take rates, a short tumor latency during PDX establishment and low survival of the corresponding patients.
Residual tumor PDX are resistant to anthracyclines, docetaxel and cisplatin, but respond to capecitabine
We determined the response to chemotherapy in 10 PDX derived from residual tumors, and compared this response with that of PDX derived from primary tumors (7) . The chemotherapy regimens used were AC (adriamycin plus cyclophosphamide), docetaxel, cisplatin and capecitabine.
Only 10%, 20% and 0% of residual TNBC PDX responded to AC, cisplatin, and docetaxel, with a TGI of at least 90%, whereas 50%, 52% and 10% of treatment-naïve TNBC PDX responded to these treatments (Fig.1E) . Conversely, residual TNBC PDX displayed a higher frequency of response to capecitabine (60%) as compared to treatment-naïve PDX (36%). Table 1 summarizes the NAC administered to patients, tumor histology, status for BRCA1/2 and TP53 mutations and response to chemotherapy, as assessed by tumor growth inhibition (TGI) and adapted RECIST criteria (13), for 10 residual TNBC PDX.
Only one residual PDX responded to AC with a TGI≥ 90%, none responded to docetaxel and two (one with a BRCA1 mutation and the other with a BRCA2 mutation) responded to cisplatin (with tumor regression observed in only one of these cases)( Table 1 and Supp. Fig. S2A ).
Six of the 10 residual PDX responded to capecitabine with a TGI≥90: four (HBCx-12A, HBCx-63, HBCx-92 and HBCx106) with stable disease and 2 models with tumor regression (HBCx-39 and HBCx-95) ( Table 1) . Three of the four capecitabine-resistant PDX corresponded to metaplastic breast cancer.
The drug response profiles of 3 capecitabine-responder PDX are illustrated in Figure 1F . Response to capecitabine was homogeneous in the different mice (Fig. 1G) 10 months after the end of treatment. A Kaplan-Meier survival curve (Supp. Fig. S2B ) showed that event-free survival was greater for animals treated with capecitabine than for animals receiving other types of chemotherapy (p=0.0004, log-rank test).
The efficacy of capecitabine in PDX is decreased by prior treatment
In the advanced setting, capecitabine is usually administered as a second or third line treatment. We hypothesized that prior treatment of tumors with a different chemotherapy regimen might affect the response to capecitabine. We tested this hypothesis in one residual TNBC PDX, through the sequential administration of chemotherapies administered to the patient in the adjuvant and metastatic settings. Patient #63 received FEC and docetaxel as NAC, followed by 5-FU and navelbine as an adjuvant treatment, then paclitaxel + bevacizumab (first line) and capecitabine (second line) in the metastatic setting ( Fig. 2A) . We administered the same treatments sequentially to the HBCx-63 PDX, established from the residual tumor, and compared it to the efficacy of capecitabine in nonpretreated tumor. Results are shown in Figure 2B : capecitabine given in xenografts pre-treated by 5-FU + navelbine or by paclitaxel + bevacizumab resulted in progressive disease in 4/5 and 6/6 xenografts (mean of 144% and 130%, respectively). By contrast, 7/9 xenografts treated with capecitabine without prior treatment displayed stable disease, one progressive disease and one tumor regression (mean=14%). Thus, prior treatment by 5-FU and navelbine decreased capecitabine efficacy.
We next analyzed the expression of two enzymes whose expression may influence capecitabine response: thymidylate synthase (TYMS), the target enzyme for 5-FU, and thymidylate phosphorylase (TYMP), an enzyme involved in the metabolism of 5-FU and capecitabine (22) . TYMS expression was increased after treatment by 5-FU and navelbine and this increase was maintained in xenografts treated by paclitaxel and bevaciuzumab (Fig. 2C) . By contrast, TYMP expression was unchanged by the different treatments (data not shown).
Research. grouped 100% of sensitive PDX together (Fig. 3B) . The 37 genes concerned are listed in Supplementary Table S3 . Three of these genes encode proteins involved in cell-cycle regulation: RB1 and CCND1, which were upregulated in responder models, and CDKN2A, which was upregulated in resistant models. Among genes implicated in capecitabine metabolism (TYMP, TYMS, TK1, DPYD), only TYMP expression was higher in responder models, although the fold change did not pass the threshold for global differential analysis (Supp. Fig. S3 ).
To validate RB at the protein level, we analyzed its expression by IHC in the 32 TNBC PDX. RB protein was detected in all 15 (100%) responder PDX and in 6/17 resistant (35%) PDX (Fig. 3C and 3D ).
Positive and negative predictive values were 71% and 100%, respectively (p=0.0001, Fisher's exact test).
We then quantified TYMP protein expression in the 32 TNBC PDX by determining the IHC H-score (21) . Examples of negative and positive TYMP IHC results are shown in Figure 3E . Thymidine phosphorylase IHC H-score was significantly higher in responder tumors (Fig. 3F) Fig. S4A ). Capecitabine had strong antitumor activity against this xenograft (TGI=99%), whereas trastuzumab did not arrest tumor growth (Supp. Fig. S4B ).
Tumor growth inhibition is correlated with a strong decrease in the expression of various RBdependent genes in capecitabine-treated xenografts
RB plays a critical role in coordinating the expression of genes required for cell-cycle progression through interaction with the transcription factor E2F. We therefore looked at the correlation between capecitabine's efficacy and the expression changes of 8 genes included in the "RB gene expression signature" and involved in cell proliferation (CCNA2, CCNB1, TOP2A, TTK, PLK1 and AURKA ) and nucleotides metabolism (TYMS, TK1) (23) . We analyzed control and post-treatment xenografts of 7 PDX, including both capecitabine-resistant and capecitabine-sensitive PDX (Fig. 4A) .
The expression levels of the eight genes, determined by RT-PCR, are shown in Supplementary Figure   S5 . A heat-map representing the fold-change difference between capecitabine-treated and control xenografts is shown in Figure 4B . All genes were strongly downregulated in the three RB-positive PDX with the highest levels of tumor growth inhibition (HBCx-63, HBCx-12A and HBCx-39), whereas no change was found in the three PDX in which capecitabine had little or no effect. The correlation between fold-change differences in gene expression and tumor growth inhibition by capecitabine is shown in Figure 4C and was statistically significant for all genes.
Inhibition of RB1 gene decreases response to 5-FU in vitro
Research. We tested whether RB1 inhibition could have an impact on capecitabine reponse in the HBCc-12A cell line, established from the RB positive HBCx-12A PDX (residual tumor derived PDX). This PDX responds to capecitabine with a TGI of 96% (stable disease with recist criteria) (Fig. 5A ). We performed a cell viability assay to determine the in vitro response of the cell line to 5-FU: the cell line showed a IC50 of 33 M (Fig. 5B ). The cell line was then transfected with 2 different siRNA directed against RB1 or control (scramble siRNA) and exposed to 40 M of 5-FU for 120H. Western blot analysis demonstrated downregulation of RB protein in cell exposed to siRB1 and siRB2, with an increased inhibition for siRB1, in both untreated and 5-FU treated cells (Fig. 5C) . Phosphorylation of RB protein was inhibited by 5-FU. Inhibition of RB1 decreased sensitivity to 5-FU of 40% as assessed by the MTT viability assay (the increased viability was greater for siRB1 as compared to siRB2) (Fig.   5D ). In summary, these results show that RB has a role in determining the cellular response to 5-FU treatment.
Discussion
We established a cohort of breast cancer PDX models by engrafting residual tumors after NAC.
Residual TNBC PDX had a higher tumor take rate and a shorter latency than TNBC PDX derived from treatment-naïve breast cancers. Both these characteristics are suggestive of an aggressive phenotype. These results are similar to those reported by McAuliffe et al who showed that take rates were higher for breast cancers treated in the neoadjuvant setting (24) . The aggressiveness of these tumors was confirmed by the poor outcomes of the corresponding patients. In more than half the TNBC patients, PDX latency was shorter than metastasis-free survival. The residual tumor PDX therefore becomes available for in vivo drug testing over a time frame compatible with clinical decision-making concerning first-line chemotherapy. Furthermore, residual TNBC PDX were resistant to anthracyclines and docetaxel-based chemotherapy. As these drugs were given to patients in the However, given the small number of cases, these results require confirmation in a larger cohort.
Responses to capecitabine were observed in six of the 10 residual tumor-derived PDXs displaying cross-resistance to anthracyclines, docetaxel and cisplatin. Three of the four capecitabine-resistant PDX were established from metaplastic breast cancers, a histological subtype of TNBC known to be particularly aggressive and resistant to chemotherapy (25) .
These findings are of particular interest for several reasons. Firstly, they are consistent with the results of a recent clinical trial (CREATE-X) demonstrating the efficacy of adjuvant capecitabine treatment in TNBC patients with residual invasive disease after neoadjuvant chemotherapy (26) .
Secondly, capecitabine treatment is well tolerated and may be compatible with adjuvant treatment in patients with a high risk of tumor recurrence. The FinXX trial also reported beneficial effects on survival in TNBC patients treated with a capecitabine-containing regimen in the adjuvant setting (27) .
In the CREATE-X trial, TNBC disease-free survival was 69.8% in the capecitabine group, versus 56.1% in the control group (26) . Thus, a large proportion of patients remained that did not benefit from adjuvant capecitabine treatment. Predictive biomarkers are crucial for identifying the patients most likely to benefit from treatment.
Based on the analysis of transcriptomic data, we identified and validated RB as a biomarker predictive of the response to capecitabine in TNBC PDX. RB is a tumor suppressor protein that regulates cell-cycle progression by preventing entry into the mitotic phase (28) . It may be inactivated by hyperphosphorylation or protein loss, both of which disrupt its association with the transcription factor E2F, facilitating the expression of a transcriptional program leading to progression through Sphase and mitosis (29) . RB is also a key regulator of cell-cycle arrest upon DNA damage (30) . The finding that capecitabine efficacy is correlated with RB expression may be explained by the role of this protein in cell-cycle control and the checkpoint response to chemotherapy. Consistent with this hypothesis, RB reconstitution in RB-deficient lung cancer cell lines re-establishes the regulation of REB/E2F target genes and restores the G1 checkpoint response to chemotherapy regimens including 5-FU (31) . Similarly, inactivation of RB1 gene by siRNA in a cell line derived from a capecitabineresponder PDX decreased sensitivity to 5-FU, further supporting a role of RB in determining the response to 5-FU/capecitabine.
In addition to its role in canonical cell cycle-dependent regulation, RB also inhibits cell proliferation 
p16(INK4a) expression by immunohistochemistry analyses in TNBC PDX will be necessary in order to validate it as potential biomarker of capecitabine resistance.
Finally, an association has been found between the RB pathway and chemotherapy response in breast cancer patients (28) . In metastatic breast cancer, mutations of the RB gene are associated with a poor response to anthracyclines (37, 38) . RB pathway inactivation is predictive of resistance to DNA damage-based treatments in locally advanced breast cancer (39) .
Capecitabine is converted to 5-FU in cancer cells TYMP enzyme (40) . Thymidine phosphorylase also activates 5-FU, by converting it to 5-fluoro-2'-deoxyuridine, a precursor of FdUMP that inhibits the TYMS enzyme, responsible for de novo thymidylate synthesis (22) . Accordingly, capecitabine-based chemotherapies have been reported to be more effective in tumors with high levels of TYMP (41-44 The evaluation of TYMP and RB as predictive biomarkers could be translated into clinical practice.
Immunohistochemical analyses of one of these two biomarkers on residual tumors at surgery could identify those patients likely to benefit from adjuvant capecitabine treatment. Retrospective validations of these biomarkers in clinical trials evaluating capecitabine against controls (like the CREATE-X study) could also be used to provide support for our results.
Our results may also have implications for the advanced cancer setting, as capecitabine is usually given as a second-or third-line treatment in patients with recurrences after NAC (46, 47) When bound to the active metabolite of 5-FU (FdUMP), TYMS is not able to bind to its mRNA which results in increased protein expression (49) . This constitutes a mechanism of acquired resistance to 5-FU (50, 51) . This case suggests that capecitabine might be more effective if introduced earlier, as adjuvant or first line treatment, and raises the question of giving 5-FU prior to capecitabine.
In conclusion, we have developed a panel of PDX models from breast cancer patients with residual disease after neoadjuvant treatment. These chemoresistant PDX provided us with an opportunity to identify effective treatment strategies that might improve the survival of patients with a high risk of relapse and poor prognosis. We showed that capecitabine was effective against 60% of TNBC PDXs derived from tumors previously treated with anthracyclines and taxanes, and we identified TYMP and RB expression as putative biomarkers predictive of the response to capecitabine. 
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